The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot missed ...

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

after trial results for its weight-loss drug CagriSema disappointed against expectations. Investors will be looking closely at the latest results from Novo Nordisk (NOVO-B.CO) – which is also ...

The stock is down about 40% from a record in June, with a chunk of the drop coming after disappointing results for a separate drug called CagriSema in December. The experimental CagriSema shot ...

Novo Nordisk is advancing its research into obesity treatments by launching new trials for its experimental drug, CagriSema. This decision follows market disappointment after previous trial results.

Novo Nordisk experienced a 16.8% decline in market capitalisation in 2024, largely driven by results from the Phase III REDEFINE 1 trial for its next-generation weight-loss drug, CagriSema ...

While the initial market reaction to Novo’s more enhanced CagriSema weight loss treatment was negative, we believe this is a more potent formulation that can better compete with Lilly’s suite.

The trial showed that patients treated with CagriSema exhibited weight loss of 22.7% after 68 weeks, well short of Novo's targeted expectation of at least 25% weight loss. The press release ...

LONDON, Jan 30 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy ...